目的:探讨达格列净联合德谷门冬双胰岛素对2型糖尿病患者的临床疗效.方法:选取2021年2月—2022年2月上海市杨浦区长白社区卫生服务中心门诊治疗的2型糖尿病患者80 例,以随机数字表法分为试验组和对照组各 40 例.试验组予口服达格列净片联合德谷门冬双胰岛素治疗,10 mg/次,1次/d;对照组仅予德谷门冬双胰岛治疗,胰岛素用量根据血糖情况进行调整,两组均治疗12周.比较两组治疗前后血糖指标[空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2 h postprandial glucose,2 h PG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)]、血脂指标[低密度脂蛋白胆固醇(low density lipoprotein,LDL-C)、甘油三酯(triglyceride,TG)、高密度脂蛋白胆固醇(high density lipoprotein,HDL-C)、总胆固醇(Total cholesterol,TC)]、肾功能指标[血肌酐(Creatinine,CREA)、尿酸(uric acid,UA)、尿微量白蛋白(Microalbuminuria,MAU)]、体质量指数(BMI)、腰围、血压(blood pressure,BP)及不良反应发生情况.结果:治疗后两组FPG、2 h PG、HbA1c、LDL-C、TG、TC、CREA、UA、MAU水平均低于治疗前(P＜0.05),且试验组低于对照组(P＜0.05);两组不良反应事件差异无统计学意义(P＞0.05).结论:达格列净联合德谷门冬胰岛素治疗2型糖尿病疗效显著,能够明显改善患者血糖指标及肾功能,降低血压、减轻体重及纠正脂代谢异常,且不会增加不良反应.
Analysis of the effect of dapagliflozin combined with IDegAsp in the treatment of type 2 diabetes mellitus
Objective:To investigate the clinical efficacy of dapagliflozin combined with insulin degludec/insulin aspart(IDegAsp)in patients with type 2 diabetes mellitus(T2DM).Methods:A total of 80 patients with T2DM treated in Outpatient Clinic of Changbai Community Health Service Center from February 2021 to February 2022 were selected and divided into an experiment group and a control group with 40 cases each by random number table method.The patients in the experiment group were treated with dapagliflozin combined with IDegAsp,10mg/time,once a day and the control group was only treated with IDegAsp,and insulin dose was adjusted based on blood glucose levels,and both groups were treated for 12 weeks.The blood glucose indexes[fasting plasma glucose(FPG),2-hour postprandial blood glucose(2 h PG),glycosylated hemoglobin(HbA1c),blood lipid indexes[low density lipoprotein(LDL-C),triglyceride(TG),high density lipoprotein(HDL-C),total cholesterol(TC)],renal function index[creatinine(CREA),uric acid(UA),microalbuminuria(MAU)],body mass index(BMI),waist,blood pressure(BP)and the incidence of adverse reactions were compared the two groups before and after treatment.Results:After treatment,FPG,2 h PG,HbA1c,LDL-C,TG,TC,CREA,UA,MAU were lower than those before in both groups,and the experiment group was lower than the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion:Dapagliflozin combined with IDegAsp has definite effect in the treatment of T2DM patients,and can improve the blood glucose level and renal function effectively,reduce the blood pressure,lose weight and correct lipid metabolism disorders and can't increase the incidence of adverse reactions in patients.
type 2 diabetes mellitusdapagliflozininsulin degludec/insulin aspart
NETL
NSTL
万方数据
